tVNS for drug-resistant epilepsy

This page is intended for UK healthcare professionals. Clinical information, including dosing parameters and effect sizes, is included.

The clinical context

Epilepsy affects approximately one in a hundred people in the UK. Two-thirds achieve satisfactory seizure control on anti-seizure medications. The remaining third, defined by the International League Against Epilepsy as having failed two or more adequately trialled ASMs, are classified as having drug-resistant epilepsy (DRE). DRE carries a substantially elevated burden: reduced quality of life, increased SUDEP risk, and significant psychological and social consequences.

For patients in this group, resective surgery offers the highest chance of seizure freedom, but only where an epileptogenic focus can be identified and safely removed. Where surgery is not viable, neuromodulation becomes the principal alternative. Of the neuromodulation options (DBS, RNS, VNS), implanted vagus nerve stimulation has the longest track record, with FDA approval since 1997.

Transcutaneous vagus nerve stimulation removes the surgical barrier entirely. It is an adjunctive, non-invasive, home-based intervention that is now supported by two substantial randomised controlled trials and a growing real-world evidence base.

The tVNS device referred to throughout this page is the tVNS® E system (tVNS Technologies GmbH, Germany), CE-marked since 2010 and holding Class IIa certification under the EU MDR 2017/745. Anatomical Concepts UK is the distributor in the UK.

Mechanism

The mechanistic picture is increasingly well characterised, though not yet complete. Four contributing pathways are worth understanding.

1. The noradrenergic pathway (the best-supported mechanism)

The auricular branch of the vagus nerve (ABVN) provides cutaneous afferent access at the cymba conchae. Vagal afferents project to the nucleus tractus solitarius (NTS) in the medulla, which sends dense projections to the locus coeruleus (LC). LC is the primary source of cortical norepinephrine. Vagal stimulation increases LC firing and elevates extracellular NE in the cortex and hippocampus. LC lesion abolishes the anti-seizure effect in animal models. In humans, LC activation during tVNS has been confirmed through pupil dilation and attenuation of occipital alpha oscillations, both established signatures of LC-NE activity.

Pharmacological studies suggest the antiepileptic effect is mediated specifically by α2-adrenoreceptor activation downstream of NE release.

2. Serotonergic and GABAergic modulation

Vagal afferents also drive activity in the raphe nuclei and elevate cortical and hippocampal GABA levels. GABAergic effects of tVNS have been demonstrated in human EEG studies after single sessions. The combined noradrenergic, serotonergic, and GABAergic modulation plausibly accounts for both the anti-seizure and mood-stabilising effects of vagal stimulation.

3. Anti-inflammatory effects

The cholinergic anti-inflammatory pathway (efferent vagal activation of α7-nicotinic acetylcholine receptors on macrophages, suppressing TNF-α and other pro-inflammatory cytokines) is better established for implanted VNS but is thought to be engaged by tVNS to some degree. Potentially relevant in epilepsies with a neuroinflammatory component.

4. Network-level stabilisation

EEG-derived functional connectivity analyses show that short-term tVNS induces measurable modifications in large-scale epileptic brain networks, enhancing resilience, stability, and robustness (properties inversely correlated with seizure propensity). The modifications differ systematically between focal and generalised epilepsy, suggesting type-specific network engagement.

Key point. The mechanisms of tVNS are multi-layered. The noradrenergic pathway through the locus coeruleus is the best-supported mechanism; serotonergic, GABAergic, anti-inflammatory, and network-level effects all appear to contribute. This mechanistic breadth may also explain the therapeutic relevance to comorbid depression.

Why the cymba conchae specifically

An fMRI study comparing four auricular sites (inner tragus, posterior canal, cymba conchae, and earlobe sham) established that cymba conchae stimulation produces the greatest and most specific activation of the NTS and locus coeruleus. The cymba conchae has 100% vagal innervation; the tragus, by contrast, has approximately 45%. Stimulation at the wrong site does not reliably activate the brainstem pathways that drive the therapeutic effect. This anatomical precision is clinically critical, and is one of the reasons the tVNS® device is designed specifically to sit in the cymba conchae.

The evidence

The cMPsE02 trial (Bauer et al., 2016)

A randomised, double-blind controlled study of 76 DRE patients randomised to 25 Hz (n=39) or 1 Hz active control (n=37) at the cymba conchae, four hours daily for 20 weeks. The intention-to-treat primary endpoint did not reach significance (23.4% vs −2.9%, p=0.146), but the completers analysis (n=26) showed a significant 34.2% reduction in the 25 Hz group (p=0.034).

Two likely explanations for the ITT result: 1 Hz stimulation may itself be biologically active, making the "control" an imperfect sham, and the trial was probably underpowered. Nevertheless, cMPsE02 provided the first randomised, double-blind evidence that high-frequency tVNS has a genuine anti-seizure effect.

Yang et al. 2023 (the strongest single piece of evidence)

A 150 patient multi-centre double-blind RCT. Adults with DRE were randomised 2:1 to active tVNS (n=100; 25 Hz, 250 µs, 30s on/30s off, 2 hours daily at maximum tolerated intensity, cymba conchae) or sham (n=50; 1 Hz at minimum perceptible intensity) for 20 weeks, across four Chinese epilepsy centres.

Results:

≥50% responder rate at 20 weeks: 44.74% active vs 16.67% control (p < 0.05)
Mean seizure reduction at 20 weeks: 30.75% active vs 15.66% control (p = 0.038)
Anti-seizure effect increased with duration, becoming significant only at 20 weeks
No severe adverse events in either group

Two observations stand out. First, a ≥50% responder rate approaching 45% is clinically meaningful for a non-invasive intervention in DRE. Second, the benefit is cumulative and emerges clearly only at 20 weeks. This has direct practical implications for setting patient expectations and for trial duration.

The trial did not show significant improvements in QOLIE-31, anxiety, depression, or cognition at 20 weeks, though the duration may have been insufficient for these secondary endpoints.

Beijing Tiantan real-world study (2024)

A prospective single-centre study of 99 DRE patients undergoing tVNS, with 1 to 2 years of follow-up. Of 65 patients with successful follow-up:

Overall efficacy rate (≥50% seizure reduction): 61.54%
15 patients (23.1%) achieved more than 90% seizure reduction
8 patients (12.3%) achieved 75 to 90% reduction
17 patients (26.2%) achieved 50 to 75% reduction
Mild adverse events (ear tingling, tinnitus) in 10 patients; no severe events

Efficacy was independent of measured clinical variables, suggesting broad applicability. The higher efficacy rate compared with the RCTs likely reflects longer follow-up and possibly greater adherence in a motivated clinical population.

Meta-analyses

Two independent meta-analyses of RCT data have been published. Both found significant reductions in seizure frequency favouring tVNS (p=0.008 in the 2026 analysis). Neither meta-analysis found a statistically significant difference in pooled responder rate, which is partly explained by the active-control problem (1 Hz is not a true sham) and partly by heterogeneity across studies. The Yang 2023 trial, with the strongest sham design, did show a significant responder rate difference, which suggests pooled estimates may underrepresent the true effect size.

Key point. The evidence base for tVNS in DRE now includes two substantial RCTs, multiple pilot studies, real-world prospective data, and two meta-analyses. The consistent finding is a statistically significant reduction in seizure frequency with a favourable safety profile. Responder rates range from just under 45% in the controlled RCT active arm (versus about 17% on control) to around 62% in uncontrolled real-world cohorts. The evidence is not yet at the level of implanted VNS, but it is substantial and growing.

Comparison with implanted VNS

No head-to-head RCT exists. With that caveat:

Feature	Implanted VNS	tVNS
Delivery	Cervical electrode + pulse generator	Auricular skin electrodes
Surgery	Yes, general anaesthetic	No
Regulatory status (epilepsy)	FDA and CE approved	CE approved (Class IIa EU MDR), not FDA approved
Responder rate (≥50%)	45 to 65% at 6 to 12 months	27 to 62% depending on study
Seizure freedom rate	5 to 10%	Not well established
Long-term data	Extensive, improving over years	Limited beyond 2 years
Stimulation mode	Continuous + on-demand; AutoStim closed loop	Open loop, 2 to 4 h/day
Stimulation side effects	Voice alteration, hoarseness, cough (10 to 40%)	Mild: ear tingling, local discomfort
Surgical complications	Infection, bradycardia, vocal cord paresis	None
Cost	Approximately £20,000 to £50,000	Hundreds to low thousands of pounds
Reversibility	Requires surgery to remove	Fully reversible

AutoStim mode in implanted VNS (responding to ictal tachycardia, present in approximately 80% of seizures) is a meaningful advantage; one series reports 69.3% ≥50% responder rate with AutoStim active. Closed-loop tVNS prototypes are under development but not yet clinically available.

Key point. tVNS is not a replacement for implanted VNS. It is an alternative, particularly suited to patients who decline surgery, are not surgical candidates, or who want to try a non-invasive approach before committing to implantation. The responder rates are somewhat lower than the best implanted VNS results, but the absence of surgical risk, full reversibility, and substantially lower cost make it a clinically rational first step in many cases.

Practical guidance

Candidate selection

Adults aged 18 and over with confirmed DRE having failed two or more ASMs (the device's intended population is adults 18+)
Not suitable for, or unwilling to undergo, resective surgery
No active implant (pacemaker, implanted defibrillator, implanted VNS, or cochlear implant) and no cerebral shunt
Not pregnant; intact skin at the electrode site; cardiac arrhythmia requires medical clearance first
Ability to maintain a consistent daily stimulation regimen

Dosing parameters

Converging on the following based on the strongest trials:

Parameter	Typical setting
Site	Left cymba conchae
Frequency	25 Hz
Pulse width	200 to 250 µs
Intensity	Maximum tolerated, sub-pain threshold (0.5 to 6 mA)
Duty cycle	30s on / 30s off
Daily duration	2 to 4 hours, divisible into sessions
Minimum trial duration	20 weeks before judging response

Left-sided stimulation follows the convention established for implanted VNS, reflecting the asymmetric cardiac innervation of the right and left vagus. The cardiac risk from auricular stimulation is anatomically much lower than for cervical stimulation.

Initiation protocol

Baseline seizure diary, a minimum of 8 weeks.
Introduce tVNS at the parameters above. Titrate intensity in the first sessions to maximum tolerated sub-pain threshold.
Maintain stable ASM regimen during the 20 week assessment window.
Brief baseline cardiac monitoring is prudent, particularly in patients with pre-existing cardiac disease.
Review at weeks 8, 12, and 20 using the seizure diary.

What to tell the patient

Anti-seizure benefit typically emerges from around 12 weeks, with the clearest effect at 20 weeks or beyond. This is not a fast intervention.
In the largest controlled trial, just under 45% of participants achieved a ≥50% reduction in seizures, versus about 17% on control. Uncontrolled real-world cohorts report higher responder rates (around 62%), but without a control group these are not directly comparable, and both 2025 meta-analyses found the pooled responder difference did not reach significance.
Expect mild local effects (tingling, redness at the electrode site). These are generally well tolerated.
The device is adjunctive. It does not replace anti-seizure medication.
Adherence matters. The benefit depends on consistent daily use.

Comorbidity considerations

Depression and anxiety are highly prevalent in DRE. The tVNS device carries an approved indication for depression in addition to epilepsy (anxiety is not among its approved indications), and the shared mechanistic basis (noradrenergic and serotonergic modulation) makes the depression overlap a clinically attractive feature. Cognitive and mood benefits may emerge more slowly than seizure benefits, so patience with the longer endpoints is warranted.

Safety

No severe device-related adverse events were reported in the pivotal controlled trials cited here. The Instructions for Use nonetheless list a range of possible effects (including, uncommonly, arrhythmia, dyspnoea, and a preliminary increase in seizures), so counsel patients accordingly.

Common, mild, transient (reported in up to 20% of patients):

Local erythema, tingling, itching at the electrode site
Headache, sleep disturbance
Ear tingling, tinnitus

Uncommon:

Transient sinus bradycardia (1 case in the Yang 150 patient RCT, self-resolving)
Nausea, dizziness, hoarseness (much less frequent than implanted VNS)

By comparison, implanted VNS carries surgical risks including infection (3 to 7%), vocal cord paresis, bradycardia during implantation, and device fracture. Cumulative stimulation side effects (hoarseness, dyspnoea) affect up to 40% of implanted VNS patients at therapeutic intensities. The avoidance of these is a significant practical advantage.

Regulatory and access context

tVNS® E device: CE marked since 2010. Class IIa under EU MDR 2017/745, verified by TÜV SÜD.
EU MDR approved indications are epilepsy, depression, chronic migraine, and Prader-Willi syndrome (per the Instructions for Use).
UK status: the device can be used in UK clinical practice under its current regulatory status. NICE has not yet issued a formal technology assessment specifically for tVNS in epilepsy; this is a gap the evidence base increasingly justifies addressing.
Distribution: Anatomical Concepts UK holds UK distribution. Warranty, returns, and support are handled in the UK.

What we do not yet know

Honest acknowledgement of the gaps matters for patient discussions.

Long-term outcomes beyond 2 years: limited controlled data.
Head-to-head comparison with implanted VNS: no RCT exists.
Closed-loop tVNS: prototypes under development, not yet clinically available.
Optimal parameter space: 25 Hz / cymba conchae / 2 to 4 h daily is empirically supported but not formally dose-optimised.
Status epilepticus: implanted VNS has shown benefit in NORSE case series; whether tVNS has a role is unanswered.

Summary

The most honest summary is this: transcutaneous vagus nerve stimulation is a clinically validated, non-invasive, adjunctive treatment for drug-resistant epilepsy. The neurophysiological rationale is well grounded. The clinical evidence, anchored by two substantial RCTs and confirmed by meta-analyses, demonstrates a significant and reproducible reduction in seizure frequency, with just under 45% of participants achieving a ≥50% reduction in the largest controlled trial (versus about 17% on control) and higher responder rates (around 62%) in uncontrolled real-world cohorts, and an excellent safety profile without surgical risk.

For patients who decline surgery, are not surgical candidates, or who have not yet tried neuromodulation, tVNS is a clinically rational option to discuss. Its accessibility, reversibility, substantially lower cost, and dual indication for comorbid mood disorders make it especially appealing in practice.

Next steps

[Book a clinician demo or call with Anatomical Concepts UK]
[Download the clinical practice guide (PDF)]
[See the full evidence library with references]
How to access the tVNS device

Key references are available in the Evidence Library. This page summarises clinical evidence current as of April 2026.